Skip to main content
Toggle navigation
Menu
Overall search
Search ClinicalINFO
In affiliation with
HIV.gov
Search
Close
Main navigation
Home
About
Guidelines
Drug Database
Glossary
News
Resources
Contact Us
English
Toggle Dropdown
English
Español (Spanish)
Home
Search Results
Overall search
Search ClinicalINFO
Search Results
701 – 720
of
3979
Table 17h. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Lipodystrophies and Weight Gain
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/lipodystrophies-and-weight-gain-full
Table 17i. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Nephrotoxic Effects
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/nephrotoxic-effects-full
Table 17j. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Osteopenia and Osteoporosis
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/osteopenia-and-osteoporosis-full
Table 17k. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Rash and Hypersensitivity Reactions
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/rash-and-hypersensitivity-reactions-full
Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/appendix-table-1-antiretrovirals-available-fixed-dose-combination-tablets-full
Fostemsavir (Rukobia, FTR)
https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-entry-attachment-inhibitors-fostemsavir-rukobia
Table 7. Situation-Specific Recommendations for Use of Antiretroviral Drugs in Pregnant People and Nonpregnant People Who Are Trying to Conceive
https://clinicalinfo.hiv.gov/guidelines/perinatal/recommendations-arv-drugs-pregnancy-situation-specific-conceive-full
Updated HHS Perinatal Antiretroviral Treatment Guidelines Released
https://clinicalinfo.hiv.gov/news/updated-hhs-perinatal-arv-treatment-guidelines-released
Pre-exposure Prophylaxis (PrEP) to Prevent HIV During Periconception, Antepartum, and Postpartum Periods
https://clinicalinfo.hiv.gov/guidelines/perinatal/pre-exposure-prophylaxis-prep-prevent-hiv
Cabotegravir
https://clinicalinfo.hiv.gov/drugs/cabotegravir-1/patient
Cabotegravir
https://clinicalinfo.hiv.gov/drugs/cabotegravir-1/patient
Cabotegravir
https://clinicalinfo.hiv.gov/drugs/cabotegravir-1/fda-label
Cabotegravir / Rilpivirine
https://clinicalinfo.hiv.gov/drugs/cabotegravir-rilpivirine/patient
Cabotegravir / Rilpivirina
https://clinicalinfo.hiv.gov/drugs/cabotegravir-rilpivirine/patient
Cabotegravir / Rilpivirine
https://clinicalinfo.hiv.gov/drugs/cabotegravir-rilpivirine/fda-label
Appendix B: Herpes (HHV-8/CMV)
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/appendix-b-herpes
What’s New in the COVID-19 and HIV Interim Guidance
https://clinicalinfo.hiv.gov/news/whats-new-covid19-hiv-interim-guidance
Fostemsavir
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/fostemsavir
Cabotegravir
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/cabotegravir
Lenacapavir (HIV prevention)
https://clinicalinfo.hiv.gov/drugs/lenacapavir-hiv-prevention
Pagination
First page
«
Previous page
‹
…
Page
32
Page
33
Page
34
Page
35
Current page
36
Page
37
Page
38
Page
39
Page
40
…
Next page
›
Last page
»